Last $122.28 USD
Change Today 0.00 / 0.00%
Volume 0.0
LZAGF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Singapore
Frankfurt
SIX Swiss Ex
As of 8:10 PM 02/24/15 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-reg (LZAGF) Key Developments

Lonza and Tigenix Sign an Agreement for the Supply of TiGenix's eASC Product, Cx601

Lonza and TiGenix announced an agreement for the supply of TiGenix's eASC product, Cx601. Under the agreement, Lonza will manufacture material for the Phase 3 trial of Cx601 in the US at Lonza's cell therapy production facility in Walkersville, Maryland (US). Cx601 is a locally-injected suspension of allogeneic expanded adipose-derived stem cells (eASCs) for the treatment of complex perianal fistulas in Crohn's disease patients, currently in Phase 3 of clinical development in Europe. Following the positive feedback received at a meeting with the Center for Biologics Evaluation and Research within the US Food and Drug Administration (FDA), TiGenix is moving ahead with the development of Cx601 for the US market. To supply Cx601 for a Phase 3 trial in the US, and potentially for the US market when the product has been fully approved, TiGenix has chosen to partner with Lonza as its contract manufacturing organisation (CMO). TiGenix will begin the process of technology transfer to Lonza in the coming weeks.

Lonza Reports Earnings Results for Full Year 2014; Provides Earnings Guidance for the Full Year 2015

Lonza reported earnings results for full year 2014. For the period, the company reported net profit nearly tripled but the life sciences group postponed issuing a target for earnings and sales this year due to Switzerland's recent decision to remove the peg of the Swiss franc to the euro. Net profit surged to CHF 237 million (USD 272 million), with both of Lonza's segments - specialty ingredients and pharma & biotech - performing well despite currency headwinds. Core earnings per share increased by more than 1/3 to CHF 6.79, reflecting lower interest rates, which substantially reduced financing cost. Core EBIT increased by 11% in constant exchange rate, which is plus 9% in reported currency or CHF 475 million. Core EBITDA margin is 20.4% and also reported EBITDA margin of 20.2% actually exceeded original guidance given mid-2012 for end of 2015. Net debt at the year end of CHF 2.0 billion. For 2015, the company expects to grow sales and profits.

Lonza Group Ltd Proposes Increased Dividend for 2014

The board of directors of Lonza Group Ltd. proposed an increased dividend to CHF 2.50 per share for 2014.

Lonza Group Ltd, 2014 Earnings Call, Jan 21, 2015

Lonza Group Ltd, 2014 Earnings Call, Jan 21, 2015

Lonza Group Ltd Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 03:00 PM

Lonza Group Ltd Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 03:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Toralf A. Haag, Chief Financial Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LZAGF:US $122.28 USD 0.00

LZAGF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Clariant AG SFr.17.44 CHF +0.23
Croda International PLC 2,716 GBp +33.00
Owens Corning $40.49 USD +0.95
Symrise AG €56.89 EUR +0.74
Wacker Chemie AG €107.34 EUR +6.21
View Industry Companies
 

Industry Analysis

LZAGF

Industry Average

Valuation LZAGF Industry Range
Price/Earnings 28.2x
Price/Sales 1.8x
Price/Book 3.1x
Price/Cash Flow 28.6x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-REG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.